Top biopharmaceutical Covid-19 vaccine companies boosted with over 80% revenue growth
Pharmaceutical Technology
SEPTEMBER 15, 2022
According to GlobalData’s report, Paxlovid, the company’s small-molecule Covid-19 oral therapy, was shown to reduce Covid-19 infections by 32% in adults and is forecast to be the top-selling drug by total sales, generating $81bn between 2021 and 2028. Bristol Myers Squibb (BMS) documented a 9.1% AbbVie reported a 22.7%
108 
Let's personalize your content